NOMIFENSINE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
ATC N06AX04
UNII 1LGS5JRP31
EPA CompTox DTXSID0023377

Structure

InChI Key XXPANQJNYNUNES-UHFFFAOYSA-N
Smiles CN1Cc2c(N)cccc2C(c2ccccc2)C1
InChI
InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H18N2
Molecular Weight 238.33
AlogP 2.85
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 1.0
Polar Surface Area 29.26
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 18.0
Assay Description Organism Bioactivity Reference
Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT) Rattus norvegicus 830.0 nM
Effect on synaptosomal uptake inhibition of Dopamine receptor None 48.0 nM
Inhibition of [3H]BTCP binding to the dopamine transporter. None 34.0 nM
Inhibition of [3H]GBR-12935 binding to the dopamine transporter. None 115.0 nM
Inhibition of [3H]WIN-35065-2 binding to the dopamine transporter. None 430.0 nM
Inhibition of [3H]WIN-35428 binding to the dopamine transporter. None 46.0 nM
Inhibition of [3H]cocaine binding to the dopamine transporter. None 120.0 nM
Inhibition of [3H]dopamine uptake at the dopamine transporter. None 240.0 nM
Binding affinity to dopamine transporter (DAT) using [3H]WIN-35428 as a radioligand None 42.66 nM
Effect on synaptosomal uptake inhibition of Noradrenaline (NA) Rattus norvegicus 6.6 nM
In vitro inhibition of [14C]norepinephrine uptake into rat hypothalamus Rattus norvegicus 18.0 nM In vitro inhibition of [14C]norepinephrine uptake into rat hypothalamus Rattus norvegicus 32.0 nM
In vitro inhibition of [3H]dopamine uptake into rat corpus striatum Rattus norvegicus 53.0 nM In vitro inhibition of [3H]dopamine uptake into rat corpus striatum Rattus norvegicus 140.0 nM
Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine None 410.0 nM
Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine None 20.0 nM
In vitro inhibition of norepinephrine uptake in rat brain synaptosomes using [3H]NE Rattus norvegicus 80.0 nM
Inhibition of norepinephrine (NE) into rat brain synaptosomes Rattus norvegicus 3.8 nM
Inhibition of dopamine (DA) uptake into rat brain synaptosomes Rattus norvegicus 79.0 nM
Inhibition of serotonin (5-HT) uptake into rat brain synaptosomes None 874.0 nM
In vitro inhibition of dopamine (DA) uptake in synaptosomal preparation of rat brain Rattus norvegicus 500.0 nM
In vitro inhibition of norepinephrine (NE) uptake in synaptosomal preparation of rat brain Rattus norvegicus 50.0 nM
Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes None 79.0 nM
Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes None 3.8 nM
Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes None 874.0 nM
Displacement of [3H]WIN-from cocaine site of dopamine transporter None 23.5 nM
Inhibition of dopamine transporter-mediated [3H]dopamine uptake in Wistar rat striatal synaptosomes by liquid scintillation spectrometry Rattus norvegicus 200.0 nM
Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting Homo sapiens 30.2 nM
Inhibition of [3H]dopamine reuptake at human recombinant DAT expressed in COS-7 cells by scintillation counting Homo sapiens 31.62 nM
Inhibition of dopamine reuptake at DAT expressed in CHO-K1 cells None 31.62 nM
Inhibition of rat NET Rattus norvegicus 20.0 nM
Inhibition of DAT None 84.0 nM
Inhibition of human NET Homo sapiens 23.0 nM
Inhibition of DAT in rat synaptosomal membrane Rattus norvegicus 26.0 nM
Inhibition of NET in rat synaptosomal membrane Rattus norvegicus 4.0 nM
In vivo DAT occupancy in sc dosed Long Evans rat striatum assessed as unbound plasma levels equaling 50% occupancy using [3H]-PE2I administered 30 mins before [3H]-PE2I 35428 challenge measured after 60 mins Rattus norvegicus 31.0 nM
In vivo NET occupancy in sc dosed Long Evans rat thalamus assessed as unbound plasma levels equaling 50% occupancy using [3H]-MeNER administered 30 mins before [3H]-MeNER challenge measured after 90 mins Rattus norvegicus 3.1 nM
Inhibition of human recombinant DAT expressed in HEK cells Homo sapiens 10.0 nM
Inhibition of human recombinant NET expressed in HEK cells Homo sapiens 5.0 nM
Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay Homo sapiens 83.0 nM Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay Homo sapiens 630.96 nM
Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay Homo sapiens 109.0 nM Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay Homo sapiens 281.84 nM
Inhibition of full-length recombinant human DAT expressed in CHOK1 cells assessed as reduction in [3H]dopamine uptake pretreated for 20 mins followed by [3H]dopamine addition measured after 10 mins by scintillation counting method Homo sapiens 15.0 nM
Binding affinity to SERT (unknown origin) Homo sapiens 874.0 nM
Binding affinity to NET (unknown origin) Homo sapiens 3.8 nM
Binding affinity to DAT (unknown origin) Homo sapiens 79.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 13.33 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.1 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.1 %

Cross References

Resources Reference
ChEBI 116225
ChEMBL CHEMBL273575
DrugBank DB04821
DrugCentral 1958
FDA SRS 1LGS5JRP31
Guide to Pharmacology 4792
PubChem 4528
SureChEMBL SCHEMBL49380
CONTENTS